Dingemanse J - Search Results

1

Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.

Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J. Hoch M, et al. Among authors: dingemanse j. Pharmacology. 2012;89(1-2):53-7. doi: 10.1159/000335367. Epub 2012 Feb 1. Pharmacology. 2012. PMID: 22302127 Clinical Trial.

2

Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic.

Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P. Dingemanse J, et al. J Clin Pharmacol. 1995 Aug;35(8):821-9. doi: 10.1002/j.1552-4604.1995.tb04126.x. J Clin Pharmacol. 1995. PMID: 8522640 Clinical Trial.

3

Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.

Dingemanse J, Wood N, Jorga K, Kettler R. Dingemanse J, et al. Br J Clin Pharmacol. 1997 Jan;43(1):41-7. Br J Clin Pharmacol. 1997. PMID: 9056051 Free article. Clinical Trial.

4

Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Dingemanse J, van Gerven JM, Schoemaker RC, Roncari G, Oberyé JJ, van Oostenbruggen MF, Massarella J, Segala P, Zell M, Cohen AF. Dingemanse J, et al. Br J Clin Pharmacol. 1997 Nov;44(5):477-86. doi: 10.1046/j.1365-2125.1997.t01-1-00612.x. Br J Clin Pharmacol. 1997. PMID: 9384465 Free PMC article. Clinical Trial.

5

Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.

Dingemanse J, Bodin F, Weidekamm E, Kutz K, van Giersbergen P. Dingemanse J, et al. J Clin Pharmacol. 2002 Mar;42(3):283-9. doi: 10.1177/00912700222011300. J Clin Pharmacol. 2002. PMID: 11865964 Clinical Trial.

6

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.

van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. van Giersbergen PL, et al. Among authors: dingemanse j. Clin Pharmacol Ther. 2002 Apr;71(4):253-62. doi: 10.1067/mcp.2002.122473. Clin Pharmacol Ther. 2002. PMID: 11956508 Clinical Trial.

7

Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.

Dingemanse J, Clozel M, van Giersbergen PL. Dingemanse J, et al. Br J Clin Pharmacol. 2002 Apr;53(4):355-62. doi: 10.1046/j.1365-2125.2002.01158.x. Br J Clin Pharmacol. 2002. PMID: 11966665 Free PMC article. Clinical Trial.

8

Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.

Dingemanse J, Clozel M, van Giersbergen PL. Dingemanse J, et al. J Cardiovasc Pharmacol. 2002 Jun;39(6):795-802. doi: 10.1097/00005344-200206000-00004. J Cardiovasc Pharmacol. 2002. PMID: 12021573 Clinical Trial.

9

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

van Giersbergen PL, Halabi A, Dingemanse J. van Giersbergen PL, et al. Among authors: dingemanse j. Br J Clin Pharmacol. 2002 Jun;53(6):589-95. doi: 10.1046/j.1365-2125.2002.01608.x. Br J Clin Pharmacol. 2002. PMID: 12047483 Free PMC article. Clinical Trial.

10

Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.

van Giersbergen PL, Bodin F, Dingemanse J. van Giersbergen PL, et al. Among authors: dingemanse j. Eur J Clin Pharmacol. 2002 Jul;58(4):243-5. doi: 10.1007/s00228-002-0459-0. Epub 2002 May 23. Eur J Clin Pharmacol. 2002. PMID: 12136369 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

334 results

Search Page